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Purpose
Most deaths in thalassemia major (TM) result from cardiac
complications due to iron overload. No data are available
in literature about possible different changes in cardiac
iron in TM patients treated with sequential deferipron-
deferoxamine (DFP-DFO) versus deferipron (DFP) and
deferoxamine (DFO) in monotherapy. Magnetic Resonance
(MR) is the unique non invasive suitable technique to eval-
uate quantitatively this issue. Our aim was to prospectively
assess in the clinical practice the efficacy of the DFP-DFO
versus DFP and DFO in monotherapy in a cohort of TM
patients by quantitative MR.
Methods
Among the first 739 TM patients enrolled in the MIOT
(Myocardial Iron Overload in Thalassemia) network,
253 patients performed a MR follow up study at 18 ± 3
months according to the protocol. We evaluated pro-
spectively the 25 patients treated with DFP-DFO versus
the 30 patients treated with DFP and the 66 patients
treated with DFO between the 2 MR scans. Myocardial
iron concentrations were measured by T2* multislice
multiecho technique.
Results
Excellent/good levels of compliance were similar in the
3 groups (DFP-DFO 96% versus DFP 97% versus DFO
92%; P=0.67). Among the patients with no significant
myocardial iron overload (MIO) at baseline (global heart
T2* ≥ 20 ms), there were no significant differences
between groups to maintain the patients without MIO
(DFP-DFO 95% versus DFP 100% versus DFO 100%;
P=0.23). Among the patients with MIO at baseline
(global heart T2* < 20 ms), only DFP and DFO showed
a significant improvement in the global heart T2* value
(P=0.001 and P=0.003, respectively) and in the number
of segment with a normal T2* value (P=0.031 and
P=0.0001, respectively). The improvement in the global
heart T2* was significantly different among groups
(mean difference global heart T2* DFP-DFO 2.2 ±
4.1 ms, DFP 10.7 ± 7.2, DFO 3.6 ± 5.4; P=0.007).
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cantly lower in the DFP-DFO versus DFP group
(P=0.014), but it was not significantly different in the
DFP-DFO versus the DFO group (P=0.63) (see figure 1).
Conclusions
Prospectively in a clinical setting over 15 months we did
not find significant differences on cardiac iron in TM
patients treated with sequential DFP-DFO versus the
TM patients treated with DFO. Conversely, DFP mono-
therapy was significantly more effective than DFP-DFO
in improving myocardial siderosis.
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